Zocor news from FiercePharma
NewsCholesterol drug market shifts
Big-name cholesterol meds are losing ground on two fronts. First, the Pfizer cholesterol drug Lipitor--its Read more...
U.S. Attys probe Schering over Vytorin
The ranks of investigators probing Schering-Plough and its Vytorin drug are broadening. In a recent SEC filing, Schering disclosed that U.S. Attorneys have been asking for info and documents related Read more...
Office upholds Pfizer's Lipitor patent
Pfizer is breathing a big sigh of relief. The U.S. Patent & Trademark Office has said it will confirm the drugmaker's basic patent on the blockbuster Lipitor drug. The office had been Read more...
Fissures in Merck, Schering relationship?
Are fault lines in the Merck/Schering-Plough joint venture beginning to open up? Market-watchers are reading the earnings-call transcripts--and the tea leaves--and finding evidence of "the Read more...
Vytorin news buried in Merck report
Read deep into Merck's first-quarter earnings report and you'll find some Vytorin secrets spilled. First off, the company expects to lose some $700 million in revenues off the blockbuster Read more...
Vytorin records created after the fact
Misleading minutes, swearing execs--just another day at the office for Vytorin's critics. Merck and Schering-Plough face new questions about their controversial Enhance trial as a Congressional Read more...
NJ will feel brunt of Schering ax
Fasten your seat belts, New Jersey, it's going to be a bumpy ride. Schering-Plough CEO Fred Hassan (photo) said that Read more...
Forbes to Big Pharma: Fess up
Big Pharma looks more and more like a big ostrich these days, Forbes suggests. The brouhaha over Vytorin and Zetia this week is a case in point. If the controversial Enhance study had proven Vytorin Read more...
Schering-Plough laying off 5,500
Schering-Plough has proven quick on the layoff trigger. The company announced a plan to cut costs by $1.5 billion by 2012 in the wake of the latest round of Vytorin controversy. Roughly 5,500 Read more...
Congress: M/S-P sat on bad news
The Vytorin onslaught continues, with Congressional committees circling and secret emails surfacing. And Merck and Schering-Plough, looking to minimize the damage, are criticizing the American Read more...
| Press ReleasesPRESS RELEASE: Cholesterol-lowering drug linked to sleep disruptions Cholesterol-lowering drug linked to sleep disruptions A cholesterol-lowering drug appears to disrupt sleep patterns of some patients, researchers reported at the American Heart Association’s Read more... |
Get more Zocor coverage at:
Paid Research Reports
- Pipeline Insight: Nosocomial Vaccines - Minefield or Goldmine?
- Drug Approval Trends at the FDA and EMEA: Process improvements, heightened scrutiny and industry response
- Biotech 2008 – life sciences industry report (online & print)
- Is there a market for alcoholism pharmacotherapies?
- New report provides Rheumatoid Arthritis market insight